Whether they go forward with the BLA will be depen
Post# of 145829
What wasn't mentioned but I'm sure is being taken into account is the 12 year exclusivity. If HIV is approved 2 years before other indications that knocks 2 years off the exclusivity for those other indications.
Of course we can slip in the backdoor with NASH/HIV patients. There is also the work of Dr. Sacha which could make leronlimab the preeminent drug in the HIV space with major market share.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)